4564.T OncoTherapy Science JPX pre-market Mar 11 2026: JPY 22.00 on heavy volume

The 4564.T stock trades pre-market at JPY 22.00 on 11 Mar 2026 after a high intraday range and 51,448,400 shares traded, placing OncoTherapy Science among Japan’s most active names. Volume and a tight 50-day average near JPY 20.92 suggest short-term trader interest. For investors we connect the pre-market flow to fundamentals, clinical catalysts, and technical signals on the JPX market

Pre-market flow and trading intensity for 4564.T stock

Pre-market action shows OncoTherapy Science (4564.T) opening interest with Open JPY 21.00, day high JPY 22.00, and volume 51,448,400 versus average 42,078,091. The share turnover explains its inclusion on most-active lists and highlights intraday liquidity for short-term traders

Fundamentals and valuation: 4564.T stock metrics

OncoTherapy Science reports EPS -2.83 and a trailing PE of -7.42, with market cap of JPY 7,216,515,579.00. Price-to-book sits at 3.54 and price-to-sales at 9.20, while the company carries a strong current ratio of 8.51, indicating ample liquidity despite negative profitability

Clinical pipeline and near-term catalysts for 4564.T stock

OncoTherapy’s pipeline includes Phase III peptide vaccine S-588410 and several small-molecule and antibody programs that drive binary clinical value; regulatory readouts or enrolment updates typically move the stock. Company site and trial updates remain the primary news drivers for price swings OncoTherapy site

Technical setup and intraday indicators for 4564.T stock

Technicals show RSI 53.65, MACD histogram 0.02, ATR 1.36, and Bollinger middle band 20.55, suggesting neutral momentum with limited trend. Short-term traders will watch break above JPY 22.00 for follow-through and support near the 50-day average at JPY 20.92

Meyka AI rates 4564.T with a score out of 100 and forecast

Meyka AI rates 4564.T with a score of 69.41 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of JPY 17.31, implying downside versus the current JPY 22.00; forecasts are model-based projections and not guarantees

Risks and opportunities in the JPX healthcare sector for 4564.T stock

Risks include clinical trial failures, dilution from equity raises, and persistent negative earnings. Opportunities derive from successful Phase III data or licensing deals that can rapidly re-rate valuation relative to peers in Japan’s Healthcare and Biotechnology groups JPX market data

Final Thoughts

4564.T stock is active pre-market on 11 Mar 2026 at JPY 22.00 with outsized volume of 51,448,400 shares, reflecting trader focus on its clinical pipeline and short-term liquidity. Fundamentals show negative earnings (EPS -2.83) and elevated valuation metrics (P/S 9.20, P/B 3.54), balanced by a strong current ratio (8.51) and cash per share JPY 6.06. Meyka AI’s forecast model projects a yearly price of JPY 17.31, which represents an implied downside of -21.31% versus the current price JPY 22.00; forecasts are model-based projections and not guarantees. Our proprietary Meyka grade (69.41/100, Grade B, HOLD) reflects mixed signals: liquidity and pipeline potential offset by weak profitability and valuation risk. Traders seeking short-term momentum can use intraday breaks above JPY 22.00 or failure below JPY 20.00 as tactical triggers, while longer-term investors should await clinical milestones or clearer revenue paths before increasing exposure. Meyka AI provides this as AI-powered market analysis and investors should perform their own due diligence

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.